IDEX Biometrics ASA

Share Issue/Capital Change • Dec 5, 2025

IDEX Biometrics ASA - Private Placement successfully placed

IDEX Biometrics ASA - Private Placement successfully placed

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR

INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, HONG KONG, JAPAN OR THE UNITED

STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR

DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER

OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, Norway, 5 December 2025.

Reference is made to the stock exchange announcement published on 4 December

2025 by IDEX Biometrics ASA ("IDEX" or the "Company") regarding a contemplated

private placement (the "Private Placement") of new shares in the Company (the

"Offer Shares").

The Private Placement has been successfully completed, raising gross proceeds

to the Company of NOK 22 million, through the issuance of 7,333,333 Offer

Shares at a subscription price per Offer Share of NOK 3 (the "Offer Price").

The Private Placement was substantially oversubscribed.

The net proceeds from the Private Placement will be used to accelerate time to

profitability, working capital needs, as well as capital expenditures and

other general corporate purposes.

Anders Storbråten (privately and through Altea AS), Robert Keith, Morten

Opstad and Kjell-Arne Besseberg have, as pre-indicated, subscribed for NOK 6,6

million, NOK 6,4 million, NOK 0.5 million and NOK 0.15 million, respectively,

in the Private Placement.

The Private Placement was divided into two tranches. Tranche 1 ("Tranche 1")

consisted of 5,690,970 Offer Shares, and the share capital increase related to

Tranche 1 have been resolved by the board of directors (the "Board") pursuant

to an authorization granted by the Company's general meeting held on 14 August

2025 (the "Authorization"). Tranche 2 ("Tranche 2") will consist of 1,642,363

Offer Shares. The issuance of Offer Shares in Tranche 2 remains subject to

approval by an extraordinary general meeting, scheduled to be held at the end

of December or early January (the "EGM"). Anders Storbråten (privately and

through Altea AS) has agreed to be allocated Offer Shares in Tranche 2 of the

Private Placement.

The completion of Tranche 1 of the Private Placement is otherwise subject to

registration of the share capital increase pertaining to issue of the Offer

Shares in the Norwegian Register of Business Enterprises. The Tranche 2 of the

Private Placement is subject to completion of Tranche 1 and approval by the

EGM. The conditions described above are jointly referred to as the

"Conditions".

Completion of Tranche 1 is not conditional upon completion of Tranche 2, and

acquisition of shares in Tranche 1 will remain final and binding and cannot be

revoked or terminated by the respective applicants if Tranche 2 is not

completed. The Applicant acknowledges that Tranche 1 and Tranche 2 of the

Private Placement will be cancelled if the Conditions are not fulfilled and

that the Board reserves the right to cancel, and/or modify the terms of the

Private Placement, at any time and for any reason prior to delivery of the

Offer Shares in Tranche 1, without or on short notice. Neither the Company nor

any of its advisors will be liable for any losses if the Private Placement is

cancelled or modified, irrespective of the reason for such cancellation or

modification.

Following completion of Tranche 1, the Company's share capital will be NOK

62,600,677 divided into 62,600,677 shares, each with a par value of NOK 1.00.

Following completion of Tranche 2 of the Private Placement, and subject to EGM

approval, the Company's share capital will be NOK 64,243,040 divided into

64,243,040 shares, each with a par value of NOK 1.00.

The payment date for the Offer Shares in Tranche 1 will be 9 December 2025.

The Offer Shares will be delivered to investors and become tradable on the

Oslo Stock Exchange once the share capital increase has been duly registered

with the Norwegian Register of Business Enterprises. Such registration will

take place following receipt of the full subscription amount from all

participating investors. The Offer Shares in Tranche 1 are expected to be

delivered on or about 11 December 2025, subject to the timely payment by

investors. The settlement of Tranche 2 of the Private Placement is expected to

take place in early January 2025.

The Board has considered the contemplated Private Placement in light of the

equal treatment obligations under the Norwegian Securities Trading Act and

Oslo Børs' Circular no. 2/2014 and deems that the Private Placement is in

compliance with these requirements. The Board holds the view that it will be

in the common interest of the Company and its shareholders to raise equity

through a private placement, in view of the current market conditions and the

growth opportunities currently available to the Company. A private placement

enables the Company to raise capital in an efficient manner, and the Private

Placement is structured to ensure that a market-based subscription price is

achieved.

Taking into consideration that the Private Placement was carried out through a

publicly announced application period, and a market based subscription price

was achieved, the Board has concluded that a subsequent offering towards

existing shareholders is not necessary.

This information is considered to be inside information pursuant to the EU

Market Abuse Regulation (MAR) and is subject to the disclosure requirements

pursuant to MAR article 17 and section 5 -12 of the Norwegian Securities

Trading Act. This stock exchange release was published by Kjell-Arne

Besseberg, Chief Operating Officer, at the time and date stated above.

About IDEX Biometrics ASA

IDEX Biometrics ASA (OSE: IDEX) is a global technology leader in fingerprint

biometrics, offering authentication solutions across payments, access control,

and digital identity. Our solutions bring convenience, security, peace of mind

and seamless user experiences to the world. Built on patented and proprietary

sensor technologies, integrated circuit designs, and software, our biometric

solutions target card-based applications for payments and digital

authentication. As an industry-enabler we partner with leading card

manufacturers and technology companies to bring our solutions to market.

Important information:

This announcement is not and does not form a part of any offer to sell, or a

solicitation of an offer to purchase, any securities of the Company. The

distribution of this announcement and other information may be restricted by

law in certain jurisdictions. Copies of this announcement are not being made

and may not be distributed or sent into any jurisdiction in which such

distribution would be unlawful or would require registration or other

measures. Persons into whose possession this announcement or such other

information should come are required to inform themselves about and to observe

any such restrictions.

The securities referred to in this announcement have not been and will not be

registered under the U.S. Securities Act of 1933, as amended (the "Securities

Act"), and accordingly may not be offered or sold in the United States absent

registration or an applicable exemption from the registration requirements of

the Securities Act and in accordance with applicable U.S. state securities

laws. The Company does not intend to register any part of the offering or its

securities in the United States or to conduct a public offering of securities

in the United States. Any sale in the United States of the securities

mentioned in this announcement will be made solely to "qualified institutional

buyers" as defined in Rule 144A under the Securities Act.

In any EEA Member State, this communication is only addressed to and is only

directed at qualified investors in that Member State within the meaning of the

EU Prospectus Regulation, i.e., only to investors who can receive the offer

without an approved prospectus in such EEA Member State. The expression "EU

Prospectus Regulation" means Regulation 2017/1129 as amended together with any

applicable implementing measures in any Member State.

This communication is only being distributed to and is only directed at

persons in the United Kingdom that are (i) investment professionals falling

within Article 19(5) of the Financial Services and Markets Act 2000 (Financial

Promotion) Order 2005, as amended (the "Order") or (ii) high net worth

entities, and other persons to whom this announcement may lawfully be

communicated, falling within Article 49(2)(a) to (d) of the Order (all such

persons together being referred to as "relevant persons"). This communication

must not be acted on or relied on by persons who are not relevant persons. Any

investment or investment activity to which this communication relates is

available only for relevant persons and will be engaged in only with relevant

persons. Persons distributing this communication must satisfy themselves that

it is lawful to do so.

Matters discussed in this announcement may constitute forward-looking

statements. Forward-looking statements are statements that are not historical

facts and may be identified by words such as "believe", "expect",

"anticipate", "strategy", "intends", "estimate", "will", "may", "continue",

"should" and similar expressions. The forward-looking statements in this

release are based upon various assumptions, many of which are based, in turn,

upon further assumptions. Although the Company believes that these assumptions

were reasonable when made, these assumptions are inherently subject to

significant known and unknown risks, uncertainties, contingencies and other

important factors which are difficult or impossible to predict and are beyond

its control.

Actual events may differ significantly from any anticipated development due to

a number of factors, including without limitation, changes in investment

levels and need for the Company's services, changes in the general economic,

political and market conditions in the markets in which the Company operate,

the Company's ability to attract, retain and motivate qualified personnel,

changes in the Company's ability to engage in commercially acceptable

acquisitions and strategic investments, and changes in laws and regulation and

the potential impact of legal proceedings and actions. Such risks,

uncertainties, contingencies and other important factors could cause actual

events to differ materially from the expectations expressed or implied in this

release by such forward-looking statements. The Company does not provide any

guarantees that the assumptions underlying the forward-looking statements in

this announcement are free from errors nor does it accept any responsibility

for the future accuracy of the opinions expressed in this announcement or any

obligation to update or revise the statements in this announcement to reflect

subsequent events. You should not place undue reliance on the forward-looking

statements in this document.

The information, opinions and forward-looking statements contained in this

announcement speak only as at its date, and are subject to change without

notice. The Company does not undertake any obligation to review, update,

confirm, or to release publicly any revisions to any forward-looking

statements to reflect events that occur or circumstances that arise in

relation to the content of this announcement.

Neither the Company's advisors nor any of their affiliates make any

representation as to the accuracy or completeness of this announcement and

none of them accepts any responsibility for the contents of this announcement

or any matters referred to herein.

This announcement is for information purposes only and is not to be relied

upon in substitution for the exercise of independent judgment. It is not

intended as investment advice and under no circumstances is it to be used or

considered as an offer to sell, or a solicitation of an offer to buy any

securities or a recommendation to buy or sell any securities in the Company.

Neither the Company's advisors nor any of its affiliates accept any liability

arising from the use of this announcement.

Contacts

Anders Storbråten, CEO and CFO, Tel: +47 416 38 582

E-mail: ir@idexbiometrics.com